Details of the Drug

General Information of Drug (ID: DMU7YEL)

Drug Name
Sufentanil
Synonyms
Chronogesic; Sufentanilum; Sufentanyl; Sulfentanil; Sulfentanyl; R 30730; R-30730; Sufenta (TN); Sufentanilum [INN-Latin]; Sufentil (TN); Sufentanil (USAN/INN); Sufentanil [USAN:BAN:INN]; N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidyl)propionanilide; N-[4-(methoxymethyl)-1-(2-thiophen-2-ylethyl)piperidin-4-yl]-N-phenylpropanamide; N-{4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]piperidin-4-yl}-N-phenylpropanamide; N-{4-[(methyloxy)methyl]-1-[2-(2-thienyl)ethyl]piperidin-4-yl}-N-phenylpropanamide; N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidinyl)-N-phenylpropanamide
Indication
Disease Entry ICD 11 Status REF
Analgesia MB40.8 Approved [1]
Therapeutic Class
Anesthetics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 386.6
Logarithm of the Partition Coefficient (xlogp) 4
Rotatable Bond Count (rotbonds) 8
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 2 h [2]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability
The bioavailability of drug is 20% [2]
Clearance
The total plasma clearance of drug is 917 L/min []
Elimination
Approximately 80% of the administered dose is excreted within 24 hours and only 2% of the dose is eliminated as unchanged drug []
Half-life
The concentration or amount of drug in body reduced by one-half in 164 minutes (in adults) []
Metabolism
The drug is metabolized via the liver []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.06467 micromolar/kg/day [4]
Unbound Fraction
The unbound fraction of drug in plasma is 0.075% [5]
Vd
The volume of distribution (Vd) of drug is 14 L []
Chemical Identifiers
Formula
C22H30N2O2S
IUPAC Name
N-[4-(methoxymethyl)-1-(2-thiophen-2-ylethyl)piperidin-4-yl]-N-phenylpropanamide
Canonical SMILES
CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC3=CC=CS3)COC
InChI
InChI=1S/C22H30N2O2S/c1-3-21(25)24(19-8-5-4-6-9-19)22(18-26-2)12-15-23(16-13-22)14-11-20-10-7-17-27-20/h4-10,17H,3,11-16,18H2,1-2H3
InChIKey
GGCSSNBKKAUURC-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
41693
ChEBI ID
CHEBI:9316
CAS Number
56030-54-7
DrugBank ID
DB00708
TTD ID
D0D8DD
VARIDT ID
DR00602
INTEDE ID
DR1508
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Opioid receptor (OPR) TTN4QDT NOUNIPROTAC Antagonist [6]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [7]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
5-hydroxytryptamine receptor 3A (HTR3A) OTAIV1AK 5HT3A_HUMAN Gene/Protein Processing [8]
Pro-opiomelanocortin (POMC) OTV41F7T COLI_HUMAN Gene/Protein Processing [9]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Sufentanil (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Moderate Increased metabolism of Sufentanil caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [10]
Emapalumab DMZG5WL Moderate Altered metabolism of Sufentanil due to Emapalumab alters the formation of CYP450 enzymes. Adaptive immunity immunodeficiency [4A01] [11]
Scopolamine DMOM8AL Moderate Additive CNS depression effects by the combination of Sufentanil and Scopolamine. Addictive disorder [6C50-6C5Z] [12]
Siltuximab DMGEATB Moderate Altered metabolism of Sufentanil due to Siltuximab alters the formation of CYP450 enzymes. Anemia [3A00-3A9Z] [11]
Methylphenobarbital DMDSWAG Major Additive CNS depression effects by the combination of Sufentanil and Methylphenobarbital. Anxiety disorder [6B00-6B0Z] [13]
Chlormezanone DMTWUXR Major Additive CNS depression effects by the combination of Sufentanil and Chlormezanone. Anxiety disorder [6B00-6B0Z] [14]
Posaconazole DMUL5EW Moderate Decreased metabolism of Sufentanil caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [15]
Desipramine DMT2FDC Moderate Additive serotonergic effects by the combination of Sufentanil and Desipramine. Attention deficit hyperactivity disorder [6A05] [16]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Sufentanil caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [17]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Sufentanil caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [15]
Telithromycin DMZ4P3A Moderate Decreased metabolism of Sufentanil caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [15]
Cariprazine DMJYDVK Major Additive CNS depression effects by the combination of Sufentanil and Cariprazine. Bipolar disorder [6A60] [14]
Erdafitinib DMI782S Moderate Increased metabolism of Sufentanil caused by Erdafitinib mediated induction of CYP450 enzyme. Bladder cancer [2C94] [18]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Sufentanil caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [19]
Tucatinib DMBESUA Moderate Decreased metabolism of Sufentanil caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [15]
Palbociclib DMD7L94 Moderate Decreased metabolism of Sufentanil caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [20]
Levomilnacipran DMV26S8 Major Additive serotonergic effects by the combination of Sufentanil and Levomilnacipran. Chronic pain [MG30] [21]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Sufentanil and Olopatadine. Conjunctiva disorder [9A60] [22]
Propofol DMB4OLE Moderate Additive CNS depression effects by the combination of Sufentanil and Propofol. Corneal disease [9A76-9A78] [23]
Mifepristone DMGZQEF Moderate Decreased metabolism of Sufentanil caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [24]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Sufentanil and Ethanol. Cystitis [GC00] [25]
MK-8228 DMOB58Q Moderate Decreased metabolism of Sufentanil caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [26]
Sertraline DM0FB1J Major Additive serotonergic effects by the combination of Sufentanil and Sertraline. Depression [6A70-6A7Z] [21]
Trimipramine DM1SC8M Moderate Additive CNS depression effects by the combination of Sufentanil and Trimipramine. Depression [6A70-6A7Z] [16]
Cyclobenzaprine DM1YBRM Major Additive CNS depression effects by the combination of Sufentanil and Cyclobenzaprine. Depression [6A70-6A7Z] [27]
Nefazodone DM4ZS8M Major Additive serotonergic effects by the combination of Sufentanil and Nefazodone. Depression [6A70-6A7Z] [21]
Paroxetine DM5PVQE Major Additive serotonergic effects by the combination of Sufentanil and Paroxetine. Depression [6A70-6A7Z] [21]
Vortioxetine DM6F1PU Major Additive serotonergic effects by the combination of Sufentanil and Vortioxetine. Depression [6A70-6A7Z] [21]
Milnacipran DMBFE74 Major Additive serotonergic effects by the combination of Sufentanil and Milnacipran. Depression [6A70-6A7Z] [21]
Escitalopram DMFK9HG Major Additive serotonergic effects by the combination of Sufentanil and Escitalopram. Depression [6A70-6A7Z] [21]
Desvenlafaxine DMHD4PE Major Additive serotonergic effects by the combination of Sufentanil and Desvenlafaxine. Depression [6A70-6A7Z] [21]
OPC-34712 DMHG57U Major Additive CNS depression effects by the combination of Sufentanil and OPC-34712. Depression [6A70-6A7Z] [14]
Clomipramine DMINRKW Moderate Additive serotonergic effects by the combination of Sufentanil and Clomipramine. Depression [6A70-6A7Z] [16]
Doxepin DMPI98T Moderate Additive serotonergic effects by the combination of Sufentanil and Doxepin. Depression [6A70-6A7Z] [16]
Maprotiline DMPWB7T Moderate Additive CNS depression effects by the combination of Sufentanil and Maprotiline. Depression [6A70-6A7Z] [16]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Sufentanil and Esketamine. Depression [6A70-6A7Z] [24]
Mepenzolate DM8YU2F Moderate Additive CNS depression effects by the combination of Sufentanil and Mepenzolate. Digestive system disease [DE2Z] [12]
Oxybutynine DMJPBAX Moderate Additive CNS depression effects by the combination of Sufentanil and Oxybutynine. Discovery agent [N.A.] [12]
Primidone DM0WX6I Major Additive CNS depression effects by the combination of Sufentanil and Primidone. Epilepsy/seizure [8A61-8A6Z] [14]
Gabapentin DM6T924 Major Additive CNS depression effects by the combination of Sufentanil and Gabapentin. Epilepsy/seizure [8A61-8A6Z] [28]
Cenobamate DM8KLU9 Moderate Increased metabolism of Sufentanil caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [29]
Phenobarbital DMXZOCG Major Additive CNS depression effects by the combination of Sufentanil and Phenobarbital. Epilepsy/seizure [8A61-8A6Z] [14]
Dantrolene DM1D8XY Major Additive CNS depression effects by the combination of Sufentanil and Dantrolene. Fever [MG26] [14]
Tolterodine DMSHPW8 Moderate Additive CNS depression effects by the combination of Sufentanil and Tolterodine. Functional bladder disorder [GC50] [12]
Miconazole DMPMYE8 Moderate Decreased metabolism of Sufentanil caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [15]
Ketoconazole DMPZI3Q Moderate Decreased metabolism of Sufentanil caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [15]
Propantheline DM2EN6G Moderate Additive CNS depression effects by the combination of Sufentanil and Propantheline. Gastric ulcer [DA60] [30]
Boceprevir DMBSHMF Moderate Decreased metabolism of Sufentanil caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [15]
Telaprevir DMMRV29 Moderate Decreased metabolism of Sufentanil caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [15]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Sufentanil caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [15]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Sufentanil caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [15]
Saquinavir DMG814N Moderate Decreased metabolism of Sufentanil caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [15]
Darunavir DMN3GCH Moderate Decreased metabolism of Sufentanil caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [31]
Conivaptan DM1V329 Moderate Decreased metabolism of Sufentanil caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [15]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Sufentanil caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [32]
Suvorexant DM0E6S3 Major Additive CNS depression effects by the combination of Sufentanil and Suvorexant. Insomnia [7A00-7A0Z] [14]
Amobarbital DM0GQ8N Major Additive CNS depression effects by the combination of Sufentanil and Amobarbital. Insomnia [7A00-7A0Z] [14]
Ramelteon DM7IW9J Major Additive CNS depression effects by the combination of Sufentanil and Ramelteon. Insomnia [7A00-7A0Z] [14]
Zaleplon DMGFWSM Major Additive CNS depression effects by the combination of Sufentanil and Zaleplon. Insomnia [7A00-7A0Z] [14]
Propiomazine DMKY8V1 Major Additive CNS depression effects by the combination of Sufentanil and Propiomazine. Insomnia [7A00-7A0Z] [14]
Tasimelteon DMLOQ1V Major Additive CNS depression effects by the combination of Sufentanil and Tasimelteon. Insomnia [7A00-7A0Z] [14]
Paraldehyde DMOC1BX Major Additive CNS depression effects by the combination of Sufentanil and Paraldehyde. Insomnia [7A00-7A0Z] [14]
ITI-007 DMUQ1DO Major Additive CNS depression effects by the combination of Sufentanil and ITI-007. Insomnia [7A00-7A0Z] [14]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Sufentanil and Polyethylene glycol. Irritable bowel syndrome [DD91] [33]
Clidinium DMUMQZ0 Moderate Additive antimotility effects by the combination of Sufentanil and Clidinium. Irritable bowel syndrome [DD91] [12]
Dicyclomine DMZSDGX Moderate Additive antimotility effects by the combination of Sufentanil and Dicyclomine. Irritable bowel syndrome [DD91] [12]
Glycerol phenylbutyrate DMDGRQO Moderate Increased metabolism of Sufentanil caused by Glycerol phenylbutyrate mediated induction of CYP450 enzyme. Liver disease [DB90-DB9Z] [11]
Brigatinib DM7W94S Moderate Increased metabolism of Sufentanil caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [34]
Ceritinib DMB920Z Moderate Decreased metabolism of Sufentanil caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [15]
PF-06463922 DMKM7EW Moderate Increased metabolism of Sufentanil caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [35]
Osimertinib DMRJLAT Moderate Decreased metabolism of Sufentanil caused by Osimertinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [11]
Selpercatinib DMZR15V Moderate Decreased metabolism of Sufentanil caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [36]
Idelalisib DM602WT Moderate Decreased metabolism of Sufentanil caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [15]
IPI-145 DMWA24P Moderate Decreased metabolism of Sufentanil caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [37]
LGX818 DMNQXV8 Moderate Increased metabolism of Sufentanil caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [38]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Sufentanil and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [39]
Exjade DMHPRWG Moderate Decreased metabolism of Sufentanil caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [40]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Sufentanil and Flibanserin. Mood disorder [6A60-6E23] [41]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Sufentanil and Thalidomide. Multiple myeloma [2A83] [42]
Prasugrel DM7MT6E Moderate Altered absorption of Sufentanil due to GI dynamics variation caused by Prasugrel. Myocardial infarction [BA41-BA43] [43]
Modafinil DMYILBE Minor Increased metabolism of Sufentanil caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [44]
Metoclopramide DMFA5MY Moderate Antagonize the effect of Sufentanil when combined with Metoclopramide. Nausea/vomiting [MD90] [45]
Granisetron DMIUW25 Major Additive serotonergic effects by the combination of Sufentanil and Granisetron. Nausea/vomiting [MD90] [46]
Dolasetron DMMG26Z Major Additive serotonergic effects by the combination of Sufentanil and Dolasetron. Nausea/vomiting [MD90] [46]
Ondansetron DMOTQ1I Major Additive serotonergic effects by the combination of Sufentanil and Ondansetron. Nausea/vomiting [MD90] [46]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Sufentanil and Bupropion. Nicotine use disorder [6C4A] [47]
Sibutramine DMFJTDI Major Additive serotonergic effects by the combination of Sufentanil and Sibutramine. Obesity [5B80-5B81] [48]
Lorcaserin DMG6OYJ Major Additive serotonergic effects by the combination of Sufentanil and Lorcaserin. Obesity [5B80-5B81] [49]
Dexfenfluramine DMJ7YDS Major Additive serotonergic effects by the combination of Sufentanil and Dexfenfluramine. Obesity [5B80-5B81] [21]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Sufentanil and Apraclonidine. Optic nerve disorder [9C40] [50]
Olaparib DM8QB1D Moderate Decreased metabolism of Sufentanil caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [24]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Sufentanil caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [51]
Flavoxate DMKV4NL Moderate Additive antimotility effects by the combination of Sufentanil and Flavoxate. Pain [MG30-MG3Z] [12]
Biperiden DME78OA Moderate Additive CNS depression effects by the combination of Sufentanil and Biperiden. Parkinsonism [8A00] [52]
Pimavanserin DMR7IVC Major Additive CNS depression effects by the combination of Sufentanil and Pimavanserin. Parkinsonism [8A00] [14]
Orphenadrine DMW542E Major Additive CNS depression effects by the combination of Sufentanil and Orphenadrine. Parkinsonism [8A00] [14]
Abametapir DM2RX0I Moderate Decreased metabolism of Sufentanil caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [53]
Methylscopolamine DM5VWOB Moderate Additive CNS depression effects by the combination of Sufentanil and Methylscopolamine. Peptic ulcer [DA61] [12]
Lefamulin DME6G97 Moderate Decreased metabolism of Sufentanil caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [54]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Sufentanil caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [15]
Ustekinumab DMHTYK3 Moderate Altered metabolism of Sufentanil due to Ustekinumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [11]
Ixekizumab DMXW92T Moderate Altered metabolism of Sufentanil due to Ixekizumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [11]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Sufentanil and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [55]
Tocilizumab DM7J6OR Moderate Altered metabolism of Sufentanil due to Tocilizumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [11]
Canakinumab DM8HLO5 Moderate Altered metabolism of Sufentanil due to Canakinumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [11]
Rilonacept DMGLUQS Moderate Altered metabolism of Sufentanil due to Rilonacept alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [11]
Golimumab DMHZV7X Moderate Altered metabolism of Sufentanil due to Golimumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [11]
Sarilumab DMOGNXY Moderate Altered metabolism of Sufentanil due to Sarilumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [11]
Quetiapine DM1N62C Major Additive CNS depression effects by the combination of Sufentanil and Quetiapine. Schizophrenia [6A20] [56]
Mesoridazine DM2ZGAN Major Additive CNS depression effects by the combination of Sufentanil and Mesoridazine. Schizophrenia [6A20] [57]
Aripiprazole DM3NUMH Major Additive CNS depression effects by the combination of Sufentanil and Aripiprazole. Schizophrenia [6A20] [14]
Iloperidone DM6AUFY Major Additive CNS depression effects by the combination of Sufentanil and Iloperidone. Schizophrenia [6A20] [14]
Paliperidone DM7NPJS Major Additive CNS depression effects by the combination of Sufentanil and Paliperidone. Schizophrenia [6A20] [14]
Perphenazine DMA4MRX Major Additive CNS depression effects by the combination of Sufentanil and Perphenazine. Schizophrenia [6A20] [14]
Molindone DMAH70G Major Additive CNS depression effects by the combination of Sufentanil and Molindone. Schizophrenia [6A20] [14]
Thiothixene DMDINC4 Major Additive CNS depression effects by the combination of Sufentanil and Thiothixene. Schizophrenia [6A20] [57]
Trifluoperazine DMKBYWI Major Additive CNS depression effects by the combination of Sufentanil and Trifluoperazine. Schizophrenia [6A20] [14]
Risperidone DMN6DXL Major Additive CNS depression effects by the combination of Sufentanil and Risperidone. Schizophrenia [6A20] [14]
Asenapine DMSQZE2 Major Additive CNS depression effects by the combination of Sufentanil and Asenapine. Schizophrenia [6A20] [14]
Pimozide DMW83TP Major Additive CNS depression effects by the combination of Sufentanil and Pimozide. Schizophrenia [6A20] [14]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Sufentanil caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [11]
Larotrectinib DM26CQR Moderate Decreased metabolism of Sufentanil caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [24]
Armodafinil DMGB035 Minor Increased metabolism of Sufentanil caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [44]
LEE011 DMMX75K Moderate Decreased metabolism of Sufentanil caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [58]
Brilinta DMBR01X Moderate Decreased metabolism of Sufentanil caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [11]
Clopidogrel DMOL54H Moderate Altered absorption of Sufentanil due to GI dynamics variation caused by Clopidogrel. Thrombosis [DB61-GB90] [43]
Sirolimus DMGW1ID Moderate Increased plasma concentrations of Sufentanil and Sirolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [55]
Tacrolimus DMZ7XNQ Moderate Increased plasma concentrations of Sufentanil and Tacrolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [55]
⏷ Show the Full List of 128 DDI Information of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 Svetel M, Tomic A, Kresojevic N, Kostic V: Pharmacokinetic drug evaluation of opicapone for the treatment of Parkinson's disease. Expert Opin Drug Metab Toxicol. 2018 Mar;14(3):353-360. doi: 10.1080/17425255.2018.1430138. Epub 2018 Jan 24.
3 BDDCS applied to over 900 drugs
4 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 mu-opioid receptor-stimulated synthesis of reactive oxygen species is mediated via phospholipase D2. J Neurochem. 2009 Aug;110(4):1288-96.
7 Possible involvement of multiple cytochrome P450S in fentanyl and sufentanil metabolism as opposed to alfentanil. Biochem Pharmacol. 1997 Jun 1;53(11):1613-9.
8 The effects of fentanyl-like opioids and hydromorphone on human 5-HT3A receptors. Anesth Analg. 2008 Jul;107(1):107-12. doi: 10.1213/ane.0b013e31817342c2.
9 Withdrawal following sufentanil/propofol and sufentanil/midazolam. Sedation in surgical ICU patients: correlation with central nervous parameters and endogenous opioids. Intensive Care Med. 2005 Mar;31(3):380-7. doi: 10.1007/s00134-005-2579-3. Epub 2005 Feb 16.
10 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
11 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
12 Product Information. Apadaz (acetaminophen-benzhydrocodone). KemPharm, Inc, Coralville, IA.
13 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
14 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
15 Bartkowski RR, Goldberg ME, Huffnagle S, Epstein RH "Sufentanil disposition. Is it affected by erythromycin administration?" Anesthesiology 78 (1993): 260-5. [PMID: 8439020]
16 Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
17 Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
18 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
19 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
20 Product Information. Ibrance (palbociclib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
21 Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
22 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
23 Gill SS, Wright EM, Reilly CS "Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study." Br J Anaesth 65 (1990): 760-5. [PMID: 2265045]
24 Cerner Multum, Inc. "Australian Product Information.".
25 Sturner WQ, Garriott JC "Deaths involving propoxyphene: a study of 41 cases over a two-year period." JAMA 223 (1973): 1125-30. [PMID: 4739371]
26 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
27 Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):.
28 Eckhardt K, Ammon S, Hofmann U, Riebe A, Gugeler N, Mikus G "Gabapentin enhances the analgesic effect of morphine in healthy volunteers." Anesth Analg 91 (2000): 185-91. [PMID: 10866910]
29 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
30 Product Information. Levorphanol Tartrate (levorphanol). Sentynl Therapeutics, Solana Beach, CA.
31 Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
32 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
33 Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
34 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
35 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
36 Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
37 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
38 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
39 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
40 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
41 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
42 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
43 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
44 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
45 Product Information. Reglan (metoclopramide). Wyeth-Ayerst Laboratories, Philadelphia, PA.
46 Canadian Pharmacists Association.
47 Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
48 Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5. [PMID: 9861909]
49 Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
50 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
51 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
52 Product Information. Artane (trihexyphenidyl). Lederle Laboratories, Wayne, NJ.
53 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
54 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
55 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
56 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
57 Cerner Multum, Inc. "Canadian Product Information.".
58 DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]